I 1111111111111111 11111 1111111111 11111 1111111111 1111111111 111111111111111111
`US009259428B2
`
`c12) United States Patent
`Lulla et al.
`
`(IO) Patent No.:
`(45) Date of Patent:
`
`US 9,259,428 B2
`*Feb.16,2016
`
`(54) COMBINATION OF AZELASTINE AND
`FLUTICASONE FOR NASAL
`ADMINISTRATION
`
`(71) Applicant: Cipla Limited, Mumbai (IN)
`
`(72)
`
`Inventors: Amar Lulla, Mumbai (IN); Geena
`Malhotra, Mumbai (IN)
`
`(73) Assignee: Cipla Limited, Mumbai (IN)
`
`( *) Notice:
`
`Subject to any disclaimer, the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(b) by O days.
`
`This patent is subject to a terminal dis(cid:173)
`claimer.
`
`(21) Appl. No.: 14/661,720
`
`(22) Filed:
`
`Mar. 18, 2015
`
`(65)
`
`Prior Publication Data
`
`US 2015/0190405 Al
`
`Jul. 9, 2015
`
`Related U.S. Application Data
`
`(60) Continuation of application No. 14/539,646, filed on
`Nov. 12, 2014, which is a continuation of application
`No. 13/644,127, filed on Oct. 3, 2012, now Pat. No.
`8,937,057, which is a continuation of application No.
`12/508,388, filed on Jul. 23, 2009, now Pat. No.
`8,318,709, which is a division of application No.
`10/518,016, filed as application No. PCT/GB03/02557
`on Jun. 13, 2003, now Pat. No. 8,168,620.
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`A61K 31156
`A61K9/00
`A61K 31155
`A61K 311573
`A61K 31158
`A61K 47110
`A61K 47118
`A61K 47126
`A61K 47138
`(52) U.S. Cl.
`CPC ............... A61K 31156 (2013.01); A61K 9/0043
`(2013.01); A61K 31155 (2013.01); A61K
`311573 (2013.01); A61K 31158 (2013.01);
`A61K 47110 (2013.01); A61K 471183
`(2013.01); A61K 471186 (2013.01); A61K
`47126 (2013.01); A61K 47138 (2013.01)
`( 58) Field of Classification Search
`None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`2,837,464 A
`3,067,197 A
`3,312,590 A
`3,506,694 A
`
`6/1958 Nobile
`12/1962 Agnello et al.
`4/ 1967 Elks et al.
`4/1970 Oxley
`
`3,557,162 A
`3,639,434 A
`3,755,302 A
`3,813,384 A
`3,828,080 A
`3,856,828 A
`3,891,631 A
`3,981,894 A
`3,989,686 A
`4,093,721 A
`4,113,680 A
`4,187,301 A
`4,188,385 A
`4,198,403 A
`4,221,787 A
`4,261,984 A
`4,263,289 A
`4,267,173 A
`4,285,937 A
`4,310,466 A
`4,335,121 A
`4,377,575 A
`4,472,393 A
`4,607,028 A
`4,710,495 A
`4,861,765 A
`4,992,474 A
`4,994,439 A
`4,996,335 A
`5,063,222 A
`5,081,113 A
`5,086,050 A
`5,164,194 A
`
`Lens et al.
`1/1971
`2/1972
`Oxley et al.
`8/1973
`Ercoli et al.
`5/1974
`Vogelsang et al.
`8/1974
`Phillipps et al.
`12/1974
`Phillipps et al.
`6/1975
`Phillipps et al.
`9/1976
`Phillipps et al.
`11/1976
`Phillipps et al.
`6/1978
`Phillipps et al.
`Kamano eta!.
`9/1978
`Edwards
`2/1980
`Edwards
`2/1980
`Alvarez
`4/1980
`Bodor et al.
`9/1980
`Alvarez
`4/1981
`4/1981
`Edwards
`5/1981
`Draper
`8/1981
`Kalvoda
`1/1982
`Edwards
`6/1982
`Phillipps et al.
`3/1983
`Stache et al.
`9/1984
`Shapiro
`8/1986
`Schmidlin
`12/1987
`Bodor
`8/1989
`Mitsukuchi et al.
`2/1991
`Skidmore et al.
`2/1991
`Longenecker et al.
`2/1991
`Bodor
`Komoto eta!.
`11/1991
`Claussner et al.
`1/1992
`2/1992
`Hettche et al.
`11/1992
`Hettche
`(Continued)
`
`AU
`BE
`DE
`DE
`DE
`DE
`DE
`EP
`EP
`EP
`
`FOREIGN PATENT DOCUMENTS
`
`12/2003
`2003244799 B2
`11/1981
`889563 Al
`6/1959
`1059906 B
`7 /1972
`2164058 Al
`5/1989
`3836579 Al
`4/2001
`19947234 Al
`5/2002
`10152369 Al
`10/1979
`0004773 A2
`0057401 Al
`8/1982
`4/1986
`0179583 Al
`(Continued)
`
`OTHER PUBLICATIONS
`
`European Search Report dated May 12, 2009, EP09075101, 2 pages.
`(Continued)
`
`Primary Examiner - Robert A Wax
`Assistant Examiner - Thor Nielsen
`(74) Attorney, Agent, or Firm - Conley Rose, P.C.; Rodney
`B. Carroll
`
`(57)
`
`ABSTRACT
`
`A pharmaceutical product or formulation, which comprises
`azelastine or a pharmaceutically acceptable salt, solvate or
`physiologically functional derivative thereof, and a steroid, or
`a pharmaceutical acceptable salt, solvate or physiologically
`functional derivative thereof, preferably the product or for(cid:173)
`mulation being in a form suitable for nasal or ocular admin(cid:173)
`istration.
`
`30 Claims, No Drawings
`
`

`

`US 9,259,428 B2
`Page 2
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`5,202,316 A
`5,232,919 A
`5,271,946 A
`5,362,721 A
`5,420,120 A
`5,608,093 A
`5,658,549 A
`5,658,919 A
`5,707,984 A
`5,830,490 A
`5,837,699 A
`5,849,265 A
`5,889,015 A
`5,914,122 A
`5,972,920 A
`5,981,517 A
`6,017,963 A
`6,057,307 A
`6,127,353 A
`6,136,294 A
`6,197,761 Bl
`6,241,969 Bl
`6,261,539 Bl
`6,294,153 Bl
`6,319,513 Bl
`6,330,938 Bl
`6,391,340 Bl
`6,395,300 Bl
`6,416,743 Bl
`6,537,983 Bl
`6,583,180 B2
`6,750,210 B2
`6,759,398 B2
`6,777,399 B2
`6,777,400 B2
`6,787,532 B2
`6,835,724 B2
`6,858,593 B2
`6,858,596 B2
`6,878,698 B2
`6,881,423 B2
`6,921,757 B2
`7,101,866 B2
`7,125,985 B2
`7,132,532 B2
`7,144,845 B2
`7,214,672 B2
`7,244,742 B2
`7,288,536 B2
`7,291,608 B2
`7,291,609 B2
`7,405,206 B2
`7,498,321 B2
`7,524,970 B2
`7,531,528 B2
`7,541,350 B2
`7,579,335 B2
`7,592,329 B2
`7,629,335 B2
`7,638,508 B2
`7,776,315 B2
`8,071,073 B2
`8,163,723 B2
`8,168,620 B2
`8,304,405 B2
`8,318,709 B2
`8,933,060 B2
`8,937,057 B2
`2002/0061281 Al
`2002/0076382 Al
`2002/0081266 Al
`2003/0018019 Al
`2004/0136918 Al
`2004/0204399 Al
`2004/0235807 Al
`
`4/1993 Claussner et al.
`8/1993 Scheffler et al.
`12/1993 Hettche
`11/1994 Stache et al.
`5/1995 Boltralik
`3/1997 Stache et al.
`8/1997 Akehurst et al.
`8/1997 Ratnaraj et al.
`1/1998 Tjoeng et al.
`11/1998 Weinstein et al.
`11/1998 Sequeira et al.
`12/1998 Li-Bovet et al.
`3/1999 Sequeira et al.
`6/1999 Otterbeck et al.
`10/1999 Seidel
`11/1999 Bodor
`1/2000 Alfonso et al.
`5/2000 Sequeira et al.
`10/2000 Yuen eta!.
`10/2000 Adjei et al.
`3/2001 Biggadike et al.
`6/2001 Saidi et al.
`7/2001 Adjei et al.
`9/2001 Modi
`11/2001 Dobrozsi
`12/2001 Herve et al.
`5/2002 Malmqvist-Granlund et al.
`5/2002 Straub et al.
`7/2002 Fassberg et al.
`3/2003 Biggadike et al.
`6/2003 Link et al.
`6/2004 Biggadike
`7/2004 Biggadike
`8/2004 Biggadike et al.
`8/2004 Biggadike et al.
`9/2004 Biggadike et al.
`12/2004 Stache et al.
`2/2005 Biggadike et al.
`2/2005 Biggadike et al.
`4/2005 Biggadike et al.
`4/2005 Dohi et al.
`7/2005 Cuenoud et al.
`9/2006 Biggadike et al.
`10/2006 Biggadike et al.
`11/2006 Biggadike et al.
`12/2006 Biggadike et al.
`5/2007 Komoto et al.
`7/2007 Pieper et al.
`10/2007 Biggadike et al.
`11/2007 Biggadike et al.
`11/2007 Biggadike et al.
`7/2008 Biggadike et al.
`3/2009 Biggadike et al.
`4/2009 John
`5/2009 Biggadike et al.
`6/2009 Biggadike et al.
`8/2009 Biggadike et al.
`9/2009 Biggadike et al.
`12/2009 Biggadike et al.
`12/2009 Biggadike et al.
`8/2010 Pairet et al.
`12/2011 Dang et al.
`4/2012 Lulla et al.
`5/2012 Lulla et al.
`11/2012 Lulla et al.
`11/2012 Lulla et al.
`1/2015 Lulla et al.
`1/2015 Lulla et al.
`5/2002 Osbakken et al.
`6/2002 Kaplan et al.
`6/2002 Woolfe et al.
`1/2003 Meade eta!.
`7/2004 Garrett et al.
`10/2004 Osbakken et al.
`11/2004 Weinrich et al.
`
`2004/0242638 Al
`2005/0163724 Al
`2005/0192261 Al
`2006/0002861 Al
`2006/0228306 Al
`2007 /0020330 Al
`2009/0124585 Al
`2009/0156567 Al
`2009/0286762 Al
`2010/0152147 Al
`2010/0311706 Al
`2012/0065177 Al
`2015/0072010 Al
`
`12/2004 Yanni et al.
`7/2005 Miyadai et al.
`9/2005 Jost-Price et al.
`1/2006 Biggadike
`10/2006 Lane
`1/2007 Dang et al.
`5/2009 Cross et al.
`6/2009 Biggadike
`11/2009 Myles et al.
`6/2010 Fuge et al.
`12/2010 Biggadike et al.
`3/2012 Myles et al.
`3/2015 Lulla et al.
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`EP
`EP
`EP
`EP
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`IL
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`0393658 Bl
`0416951 Al
`0780127 Al
`1519731 Bl
`2072051 Al
`2075000 Al
`1191965
`1296458
`1384372
`1438940
`1517278
`2079755 A
`2088877 A
`2140800 A
`2389530 A
`109656 A
`4208267 A
`8291072 A
`8291073 A
`200253485 A
`8504589 Al
`8903390 Al
`9015816 Al
`9104252 Al
`9214472 Al
`9531964 Al
`9619199 Al
`9632151 Al
`9701337 Al
`9705136 Al
`9715298 Al
`9721721 Al
`9721724 Al
`9724365 Al
`9731626 Al
`9740836 Al
`9746243 Al
`9817676 Al
`9834596 A2
`9848839 Al
`9901467 A2
`9925359 Al
`9932089 Al
`0016814 Al
`0033892 Al
`0038811 Al
`0048587 Al
`0049993 A2
`0066522 Al
`0104118 A2
`01020331 Al
`0154481 A2
`0154664 Al
`0157025 Al
`0162722 A2
`0178736 Al
`0178739 Al
`0178741 Al
`0178745 Al
`0200199 Al
`0200679 A2
`0202565 A2
`0207767 A2
`
`10/1990
`3/1991
`6/1997
`4/2009
`6/2009
`7/2009
`5/1970
`11/1972
`2/1975
`6/1976
`7 /1978
`1/1982
`6/1982
`12/1984
`12/2003
`2/1998
`7 /1992
`11/1996
`11/1996
`2/2002
`10/1985
`4/1989
`12/1990
`4/1991
`9/1992
`11/1995
`6/1996
`10/1996
`1/1997
`2/1997
`5/1997
`6/1997
`6/1997
`7 /1997
`9/1997
`11/1997
`12/1997
`4/1998
`8/1998
`11/1998
`1/1999
`5/1999
`7 /1999
`3/2000
`6/2000
`7/2000
`8/2000
`8/2000
`11/2000
`1/2001
`3/2001
`8/2001
`8/2001
`8/2001
`8/2001
`10/2001
`10/2001
`10/2001
`10/2001
`1/2002
`1/2002
`1/2002
`1/2002
`
`

`

`US 9,259,428 B2
`Page 3
`
`(56)
`
`References Cited
`
`FOREIGN PATENT DOCUMENTS
`
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`ZA
`
`0208243 Al
`0211711 A2
`0212265 Al
`0212266 Al
`0213868 Al
`0226723 Al
`0236106 A2
`02051422 Al
`02053186 A2
`02066422 Al
`02070490 Al
`02076933 Al
`02085296 A2
`02088167 Al
`02100879 Al
`03000241 A2
`03013427 A2
`03033000 Al
`03035668 A2
`03040691 A2
`03042229 Al
`03042230 Al
`03048181 Al
`03062259 A2
`03064445 Al
`03066033 Al
`03066036 Al
`03066656 Al
`03072592 Al
`03086399 Al
`03105856 Al
`2004013156 Al
`2004019955 Al
`2005005451 Al
`2005005452 Al
`2006058022 Al
`2007061454 Al
`2008012338 A2
`2008012338 A3
`872389
`
`1/2002
`2/2002
`2/2002
`2/2002
`2/2002
`4/2002
`5/2002
`7/2002
`7/2002
`8/2002
`9/2002
`10/2002
`10/2002
`11/2002
`12/2002
`1/2003
`2/2003
`4/2003
`5/2003
`5/2003
`5/2003
`5/2003
`6/2003
`7/2003
`8/2003
`8/2003
`8/2003
`8/2003
`9/2003
`10/2003
`12/2003
`2/2004
`3/2004
`1/2005
`1/2005
`6/2006
`5/2007
`1/2008
`1/2008
`4/1987
`
`OTHER PUBLICATIONS
`
`Settipane, Guy, et al., "Triamcinolone acetonide aqueous nasal spray
`in patients with seasonal ragweed allergic rhinitis: a placebo-con(cid:173)
`trolled, double-blind study," Clinical Therapeutics, 1995, vol. 17, No.
`2, pp. 252-263.
`Shapiro, Elliot L., et al., "17 heteroaroyl esters of corticosteroids 2.
`l li3-hydroxy series," Journal of Medicinal Chemistry, vol. 30, No. 9,
`1987, pp. 1581-1588, American Chemical Society.
`Shapiro, Elliot, et al., "17-esters and 17,21-diesters of 9-a, 11-13-
`dichlorocorticoids. Synthesis and anti-inflammatory activity," Ste(cid:173)
`roids, vol. 9, No. 2, pp. 143-156, Feb. 1967.
`Shapiro, Elliot L., et al., "Synthesis and structure-activity studies of
`corticosteroid 17-heterocyclic aromatic esters. 1. 9a, 1113-dichloro
`series," Journal of Medicinal Chemistry, vol. 30, No. 6, pp. 1068-
`1073, 1987, American Chemical Society.
`Shenfield, Gillian M., "Fixed drug combinations: which ones can be
`recommended?" Current Therapeutics, Dec. 1986, pp. 15, 16, 22-24,
`27-29.
`Simpson, Richard J., "Budesonide and terfenadine, separately and in
`combination, in the treatment of hay fever,"Annals of Allergy, Dec.
`1994, vol. 73, pp. 497-502 plus cover and publication pages, Ameri(cid:173)
`can College of Allergy and Immunology.
`Smith, Carolyn L., et al., "In vitro glucocorticoid receptor binding
`and transcriptional activation by topically active glucocorticoids,"
`Arzneim-Forsch./Drug Res., 1998, vol. 48 (II), No. 9, pp. 956-959.
`Smith, N., et al., "Comparison of the electroosmotic flow profiles and
`selectivity
`of
`stationary
`phases
`used
`in
`capillary
`electrochromatography," Journal of Chromatography A., vol. 832,
`1999, pp. 41-54, Elsevier Science B.V.
`
`Souness, et al., "Immunosuppressive and anti-inflammatory effects
`of cyclic AMP phosphodiesterase (PDE) type 4
`inhibitors,"
`Immunopharmacology, 2000, vol. 47, pp. 127-162, Elsevier Science
`B.V.
`Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," J
`Allergy Clin Immunol, 1999, vol. 103, No. 3, Part 2, pp. S386-S387,
`Mosby, Inc.
`Study No. 03DMW062-"Pharmacokinetics of GW685698X and
`CCI18781 (fluticasone propionate) when co-administered by the
`intratracheal or intravenous route to the anaesthetised white pig,"
`2004, 21 pages.
`Study No. B30947-"The Pharmacokinetics of GW685698X and
`CCil 8781
`following
`intratracheal co-administration
`to
`the
`anaesthetised white pig," 2003, 20 pages.
`Szefler, Stanley J., et al., Chapter 21, "Glucocorticoids in severe
`asthma: mechanisms of action and route of administration," Difficult
`Asthma, pp. 371-375, Martin Dunitz Ltd, 1999.
`Tanaka, Akira, et al., "Synthesis of 4H-furo[3,2-b]indole derivatives.
`III (1). Preparation of 4H-furo[3,2-b]indole-2-carboxylic acid
`derivatives," vol. 16, pp. 785-788, Jun. 1979, HeteroCorporation.
`The United States Pharmacopoeia,
`23rd Edition, U.S.
`Pharmacopoeia Convention, Inc., 1995, pp. 1843-1844, "Physical
`Tests/ X-ray Diffraction (941)."
`Ueno, Hiroaki, et al., "Synthesis and evaluation of antiinflammatory
`activities of a series of corticosteroid l 7a-esters containing a func(cid:173)
`tional group," Journal of Medicinal Chemistry, vol. 34, No. 8, 1991,
`pp. 2468-2473.
`Van As, Andre, et al., "Once daily flluticasone propionate is as effec(cid:173)
`tive for perennial allergic rhinitis as twice daily beclomethasone
`dipropionate," J. Allergy Clin. Immunol., 1993, vol. 91, No. 6, pp.
`1146-1154.
`Van Bavel, , J. H., et al., "Ocular efficacy and clinician overall
`evaluation of intranasal fluticasone proprionate (FP) versus
`loratadine (LOR) in seasonal allergic rhinitis (SAR)," Annals of
`Allergy, Asthma, & Immunology, 1997, vol. 78, p. 128, Abstract
`Pl 01.
`Van Der Molen, T., et al., "Effects of the long acting 13 agonist
`formoterol on asthma control in asthmatic patients using inhaled
`corticosteroids," Thorax, vol. 52, 1996, pp. 535-539 plus information
`page.
`Vanrell, Herrero, "Preservatives in ophthalmic formulations: an over(cid:173)
`view," Arch Soc Esp Oftalmol, 2007, vol. 82, pp. 531-532.
`Veramyst™ (fluticasone furoate) Nasal Spray, GlaxoSmithKline,
`Apr. 2007, Summary Sheet, pp. 1-20.
`Wang, De-Yun, "Treatment of Allergic Rhinitis: Hl-Antihistamines
`and Intranasal Steroids," Current Drug Targets-Inflammation &
`Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
`Westlund, Ronald, et al., "Fluticasone propionate aqueous nasal
`spray 200 mg once daily provides relief of ocular symptoms associ(cid:173)
`ated with seasonal allergic rhinitis," 57th Annual Meeting of the
`American Academy of Allergy, Asthma and Immunology, New
`Orleans, Louisiana, Mar. 16-21, 2001, Abstract No. 522, 1 page.
`World Review 2001: The Pharmaceutical Market, vol. 1 Interna(cid:173)
`tional, IMS Health, 2001, cover, preface, and copyright pages plus
`pp. 4-42 and 5-1 through 5-11, IMS A.G.
`Foreign communication from a related counterpart application-Pre(cid:173)
`Grant Opposition, 1696/MUMNP/2009, Jun. 27, 2012, 124 pages.
`PCT/GB0l/03495, International Search Report, Oct. 17, 2001, 2
`pages.
`PCT/GB0 1/03495, International Preliminary Examination Report,
`Aug. 30, 2002, 11 pages.
`PCT/EP2007/057695, International Search Report and Written
`Opinion, Oct. 28, 2008, 16 pages.
`PCT/EP2007 /057695, International Preliminary Report on Patent(cid:173)
`ability, Feb. 3, 2009, 8 pages.
`Document submitted in the Opposition proceedings regarding Euro(cid:173)
`pean Patent No. 1519731, D3 5, Units and Sales for Corticosteroids in
`2009 and 2010, Oct. 5, 2011, 3 pages.
`Document submitted in the Opposition proceedings regarding Euro(cid:173)
`pean Patent No. 1519731, D36, Stability tests, Oct. 5, 2011, 4 pages.
`Office Action dated Jul. 11, 2011-20632 IL, 3 pages.
`Office Action dated Mar. 29, 2011 (3 pages) from counterpart appli(cid:173)
`cation, AU2009243422.
`
`

`

`US 9,259,428 B2
`Page 4
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`European Search Report dated May 12, 2009, EP09075100, 3 pages.
`Sandham, David A., et al., "Synthesis and biological properties of
`novel glucocorticoid androstene C-17 furoate esters," Bioorganic &
`Medicinal Chemistry, 2004, vol. 12, pp. 5213-5224, Elsevier Ltd.
`Scadding, Glenis K., et al., "Clinical and physiological effects of
`fluticasone propionate aqueous nasal spray in the treatment of peren(cid:173)
`nial rhinitis," Rhinology, 1991, Suppl. 11, pp. 37-43.
`Schmidt, Bernhard M. W., et al., "The New Topical Steroid
`Ciclesonide is Effective in the Treatment of Allergic Rhinitis," Jour(cid:173)
`nal of Clinical Pharmacology, 1999, vol. 39, pp. 1062-1069, Ameri(cid:173)
`can College of Clinical Pharmacology.
`Ong, John T. H., et al., "Intrinsic potencies of novel thiol ester
`corticosteroids RS-85095 and RS-21314 as compared with
`clobetasol 17-propionate and fluocinonide," Arch Dermatol, vol.
`125, Dec. 1989, pp. 1662-1665.
`Ong, John T. H., et al., "Micellar solubilization oftimobesone acetate
`in aqueous and aqueous propylene glycol solutions of nonionic
`surfactants," Pharmaceutical Research, vol. 5, No. 11, 1988, pp.
`704-708, Plenum Publishing Corporation.
`Onrust, Susan B., et al., "Mometasone furoate: a review of its
`intranasal use in allergic rhinitis," Drugs, vol. 56, No. 4, Oct. 1998,
`pp. 725-745, Adis International Limited.
`Opponent's submission dated Oct. 6, 2011 to European Patent No.
`1519731, 2 pages.
`Opponent's submission dated Sep. 23, 2011 regarding additional
`documents on European Patent No. 1519731, 2 pages.
`Opponent's submission dated Sep. 23, 2011 regarding list of attend(cid:173)
`ees at oral proceedings on European Patent No. 1519731, 1 page.
`Patentee's response of Sep. 6, 2010 of European Patent No. 1519731,
`49 pages.
`Opposition to EP 1519731, Aug. 8, 2011, 19 pages.
`Patentee's submission dated Sep. 19, 2011 on European Patent No.
`1519731, 1 page.
`Patentee's submission dated Sep. 29, 2011 regarding list ofattendees
`at oral proceedings on EP Patent No. 1519731, 1 page.
`Phillipps, Gordon H., et al., "Synthesis and structure-activity rela(cid:173)
`tionships in a series of anti-inflammatory corticosteroid analogues,
`and-1713-
`halomethyl
`androstane-17!3-carbothioates
`carboselenoates," Journal of Medicinal Chemistry, 1994, vol. 37, No.
`22, pp. 3717-3729, American Chemical Society.
`Popper, Thomas L., et al., "Structure-activity relationships of a series
`of novel topical corticosteroids," J. steroid Biochem., 1987, vol. 27,
`No. 4-6, pp. 837-843, Pergamon Journals Ltd.
`Portmann, D. et al., Acceptability of local treatment of allergic
`rhinitis with a combination of a corticoid (beclomethasone) and an
`antihistaminic (azelastine), XP-002252974, 2000, 1 page, Medline.
`Pre-Grant Opposition, Indian Patent Application 2092/KOLNP/2007
`dated Jun. 8, 2007, 183 pages.
`Prescribing Information for ASTEPRO®, Nov.2010, 20 pages, Meda
`Pharmaceuticals Inc.
`Prescribing Information for RHINOCORT AQUA®, Dec. 2010, 32
`pages, AstraZeneca LP.
`Preservative, definition of. Composite definition of preservative in
`the Medical dictionary, from internet site http:/ !medical-dictionary.
`thefreedictionary.corn/preservative, Nov. 4, 2009, 3 pages.
`Product Information RhinocortAqua® (budesonide) Nasal Spray 32
`mcg, Jan. 2005, 2 pages.
`Product Information, N asonex® (mometasone furoate monohydrate)
`Nasal Spray 50 mcg, Aug. 2001, 22 pages, Schering Corporation.
`Product Specification Bulletin, Avicel® CL-611, Bulletin AVC61 l(cid:173)
`SPEC-02/09.RS, Feb. 2009, 2 pages, FMC Corporation.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-
`SPEC-02/09.RS, Feb. 2009, 2 pages, FMC Corporation.
`
`Rapid Response Report: Summary with Critical Appraisal,
`"Fluticasone Furoate versus Fluticasone Propionate for Seasonal
`Allergic Rhinitis: A Review of the Clinical and Cost Effectiveness,"
`Jun. 13, 2011, 8 pages, Canadian Agency for Drugs and Technologies
`in Health.
`Ratner, Paul H., et al., "A Comparison of the Efficacy ofFluticasone
`Propionate Aqueous Nasal Spray and Loratadine, Alone and in Com(cid:173)
`bination, for the Treatment of Seasonal Allergic Rhinitis," The Jour(cid:173)
`nal of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125 plus
`cover and publishing pages, Appleton & Lange.
`Ratner, Paul H., et al., "Combination therapy with azelastine hydro(cid:173)
`chloride nasal spray and fluticasone propionate nasal spray in the
`treatment of patients with seasonal allergic rhinitis," Annals of
`Allergy, Asthma & Immunology, Jan. 2008, vol. 100, pp. 74-81.
`Reddy, Indra K., "Ocular Therapeutics and Drug Delivery: A Multi(cid:173)
`Disciplinary Approach," 1996, pp. 382-385 plus cover and publish(cid:173)
`ing pages, Technomic Publishing Company, Inc.
`Result of oral proceedings dated Oct. 12, 2011 of EP Patent No.
`1519731, 5 pages.
`Safety Data Sheet No. 110536, Jun. 23, 2008, Version 13, Beconase
`Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.
`Safety Data Sheet No. 110556, Jul. 4, 2008, Version 14, Flonase
`Nasal Spray, 5 pages, GlaxoSmithKline.
`Sakagami, Masahiro, et al., "Mucoadhesive BDP microspheres for
`powder inhalation-their unique pharmacokinetic-pharmacodynamic
`profiles," Respiratory Drug Delivery, vol. VI, pp. 193-199, 1998.
`Salib, Rarni Jean, et al., "Safety and Tolerability Profiles oflntranasal
`Antihistamines and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis," Drug Safety, 2003, vol. 26, No. 12, pp. 863-893
`plus cover and publishing pages, ADIS Data Information BV.
`Baldwin C. M., et al., abstract, "Mometasone furoate: a review of its
`intranasal use in allegic rhinitis," 2008, 1 page, [Drugs, pp. 1723-
`1739, vol. 68, No. 12].
`Bielory, L., et al., "Impact of mometasone furoate nasal spray on
`individual ocular symptoms of allergic rhinitis: a meta-analysis,"
`Allergy, 2011, pp. 686-693, vol. 66, John Wiley & Sons A/S.
`Clinica!Trials.gov, "A study of the effectiveness and safety of
`mometasone furoate nasal spray (MFNS,SCH032088) for the treat(cid:173)
`ment of nasal polyps (P05604)," http://clinicaltrials.gov/ct2/show/
`NCT01386125, Mar. 14, 2013, 3 pages, Merck.
`Clinica!Trials.gov, "Mometasone furoate nasal spray for treatment of
`nasal polyposis after surgery (study P03218)," http://clinicaltrials.
`gov/ct2/show/NCT00731185, Aug. 7, 2008, 3 pages, Schering(cid:173)
`Plough.
`Makihara, Seiichiro, et al., "Early interventional treatment with
`intranasal mometasone furoate in Japanese cedar/cypress pollinosis:
`a randomized placebo-controlled trial," Allergology International,
`2012, pp. 295-304, vol. 61, No. 2, Japanese Society of Allergology.
`Small, Catherine Butkus, et al, "Efficacy and safety of mometasone
`furoate nasal spray in nasal polyposis," J Allergy Clin Immunol, Dec.
`2005, pp. 1275-1281, American Academy of Allergy, Asthma and
`Immunology.
`Stjiirne, Par, et al., "Use of mometasone furoate to prevent polyp
`relapse after endoscopic sinus surgery," Arch Otolaryngol Head Neck
`Surg, Mar. 2009, pp. 296-302, vol. 135, No. 3, American Medical
`Association.
`Vuralkan, Erkan, et al., "Comparison of montelukast and
`mometasone furoate in the prevention of recurrent nasal polyps,"
`2012, pp. 5-10, vol. 6, No. 1, Therapeutic Advances in Respiratory
`Disease.
`Office communication dated Jul. 6, 2011 (3 pages), U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Office Action dated Jul. 15, 2013 (48 pages), U.S. Appl. No.
`13/204,978, filed Aug. 8, 2011.
`Clinicaltrials.gov, "Efficacy and safety of mometasone furoate plus
`azelastine HCI combination versus mometasone furoate alone or
`azelastine alone
`in patients with perennial allergic rhinitis
`(NCT0 1470053 )," http://clinicaltrials.gov/ ct2/ show/NCT0 14 70053,
`Aug. 26, 2013, 3 pages, Hanlim Pham. Co., Ltd.
`1 page summary of "Evaluation of fluticasone propionate aqueous
`nasal spray taken alone and in combination with cetirizine in the
`prophylactic treatment of seasonal rhinitis," Drug Investigation, Oct.
`1994, vol. 8, Issue 4, pp. 225-233.
`
`

`

`US 9,259,428 B2
`Page 5
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Finn, Jr., A. F., et al., 1 page abstract of "Efficacy of three different
`dosing regimens of fluticasone propionate (FP) aqueous nasal spray
`in the treatment of perennial nonallergic rhinitis (PNAR)," J Allergy
`Clin Immunol, Jan. 1997, Ref. No. 1787.
`Graft, David, et al., "A placebo- and active-controlled randomized
`trial of prophylactic treatment of seasonal allergic rhinitis with
`mometasone furoate aqueous nasal spray," J Allergy Clin Immunol,
`Oct. 1996, pp. 724-731, vol. 98, No. 4, Mosby-Year Book, Inc.
`Marazzi, P., et al., 1 page abstract of"Prophylactic use of once-dailly
`mometasone furoate (Nasonex) aqueous nasal spray in patients with
`seasonal allergic rhinitis," J Allergy Clin Immunol, Jan. 1997, Ref.
`No.1789.
`Nakabayashi, S., et al., 1 page abstract of "The effect of initial
`treatment by FP aqueous nasal spray in patients with Japanese cedar
`pollinosis," Sep. 1996, vol. 99, No. 9, pp. 1162-1171.
`Simon, Michael W., 1 page abstract of "The efficacy of azelastine in
`the prophylaxis of acute upper respiratory tract infections," Allergy &
`Immunology, Dec. 2003, vol. 16, No. 4, pp. 275-282.
`Trangsrud, Amanda J., et al., "Intranasal corticosteroids for allergic
`rhinitis," Pharmacotherapy, 2002, vol. 22, No. 11, 14 pages,
`Pharmacotherapy Publications.
`Yamagishi, Masuo, et al., 1 page abstract of"Azelastine in the treat(cid:173)
`ment and prevention of seasonal grass pollinosis," Practica Oto(cid:173)
`Rhino-Laryngologica, 1991, pp. 1345-1353, vol. 84, No. 9.
`"Allergic Rhinitis and its Impact on Asthman (ARIA) 2008," Euro(cid:173)
`pean Journal of Allergy and Clinical Immunology, Apr. 2008, 162
`pages, vol. 63, No. 86, Wiley-Blackwell, Copenhagen, Denmark.
`Aria Workshop Report entitled "Allergic Rhinitis and its Impact on
`Asthma," The Journal of Allergy and Clinical Immunology, Nov.
`2001, 205 pages, vol. 108, No. 5, Mosby.
`Astelin Product Information, Jul. 2011, 8 pages, Meda Pharmaceu(cid:173)
`ticals Inc.
`Berger, William E., et al., "Double-blind trials of azelastine nasal
`spray monotherapy versus combination therapy with loratadine tab(cid:173)
`lets and beclomethasone nasal spray in patients with seasonal allergic
`rhinitis," Annals of Allergy, Asthma & Immunology, Jun. 1999, pp.
`535-541, vol. 82.
`Communication of Notice of Opposition in a foreign counterpart
`application, European Patent No. 2072051, Nov. 6, 2014, 19 pages.
`Comparative Composition data of Azelastine with steriods table filed
`by patentee, 20632A-EP, Nov. 2, 2010, 2 pages.
`European Sales Data Table, 2001-2005, 3 pages.
`Nasacort® AQ (triamcinolone acetonide) Product Leaflet, Nov.
`2010, 5 pages, sanofi-aventis U.S. LLC.
`Opponent/ Appellant's Statement of Grounds of Appeal against the
`Interlocutory Decision in Opposition Proceedings in a foreign coun(cid:173)
`terpart application, European Patent No. 1519731 Bl, May 28, 2012,
`62 pages.
`Pawankar, Ruby, "Allergic Rhinitis and Its Impact on Asthma: An
`Evidence-Based Treatment Strategy for Allergic Rhinitis," Asian
`Pacific Journal of Allergy and Immunology, Mar. 2002, pp. 43-52
`plus 1 page publishing information, vol. 20, No. 1, Allergy, Asthma
`and Immunology Society of Thailand.
`Reichmuth, Daniel, et al., "Present and Potential Therapy for Allergic
`Rhinitis," BioDrugs, Dec. 2000, pp. 371-387, vol. 14, No. 6, Adis
`International Limited.
`Reply of Patentee to Grounds of Appeal in a foreign counterpart
`application, European Patent No. 1 519 731 Bl, Feb. 14, 2013, 46
`pages.
`Rote Liste® catalog of drugs marketed in Germany in the year 2002,
`entries 07 079 and 07 080 (Allergodil, nasal spray (solution)), and 72
`025 (Nasonex, nasal spray (suspension)), 3 pages, Rote Liste® Ser(cid:173)
`vice GmbH, Frankfurt.
`Scadding, G. K., "Clinical assessment of antihistamines in rhinitis,"
`Clinical and Experimental Allergy, 1999, pp. 77-81, vol. 29, No. 3,
`Blackwell Science Ltd.
`
`Stricker, W. E., et al., "Fluticasone Propionate Aqueous Nasal Spray
`(FP) and Loratadine (LOR), Alone and in Combination, in the Treat(cid:173)
`ment of Fall Seasonal Allergic Rhinitis (SAR)," Ref. No. P62, Jan.
`1998,p. 115,vol.80.
`Sur, Denise K., et al., "Treatment of Allergic Rhinitis," American
`Family Physician, Jun. 15, 2010, pp. 1440-1446, vol. 81, No. 12,
`American Academy of Family Physicians.
`USP Monographs: Flunisolide Nasal Solution, 2013, 2 pages, USPC.
`Lieberman, Phil, "Treatment Update: Nonallergic Rhinitis," Allergy
`andAsthmaProceedings, Jul.-Aug. 2001,pp.199-202, vol. 22, No. 4.
`Van Cauwenberge, P., et al., "Consensus statement on the treatment
`ofallergic rhinitis," Allergy, 2000, pp. 116-134, vol. 55, Munksgaard,
`United Kingdom.
`"Nasal Polyp," Wikipedia entry, http://en.wikipedia.org/wiki/Na(cid:173)
`sal_polyp, downloaded from Internet on Apr. 3, 2013, 4 pages.
`Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone
`propionate combination with budesonide in patients with mild-to(cid:173)
`moderate asthma," http://www.medscape.com/viewarticle/406237 _
`print, [Clin Drug Invest, vol. 21, No. 9, 2001, pp. 633-642], Adis
`International Limited.
`Johnson, Malcom, "Development of fluticasone propionate and com(cid:173)
`parison with other inhaled corticosteroids," J Allergy Clin Immunol,
`Apr. 1998, vol. 101, No. 4, Part 2, pp. S434-S439, Mosby, Inc.
`Juniper, E. F., et al., "Comparison ofbeclomethasone dipropionate
`aqueous nasal spray, astemizole, and the combination in the prophy(cid:173)
`lactic treatment of ragweed pollen-induced rhinoconjunctivitis,"
`Journal of Allergy and Clinical Immunology, Mar. 1989, vol. 83, No.
`3, cover and publication pages, pp. 627-633, American Academy of
`Allergy and Immunology, C.V. Mosby Co.
`Knobil, K., et al., "Adding salmeterol is more effective than increas(cid:173)
`ing the dose of fluticasone for patients with asthma who are symp(cid:173)
`tomatic on low dose fluticasone," European Respiratory Journal, vol.
`12, Suppl. 29, Dec. 1998, pp. 19s-20s plus 1 cover page, Ref. No.
`Pl 60.
`Kooreman, H. J., et al., "The synthesis of 17-esters of corticosteroids
`protection of 1113-hydroxyl of the trimethylsilyl group," Synthetic
`Communications, vol. 1, No. 2, pp. 81-87, 1971, Marcel Dekker, Inc.
`Laforce, Craig F., et al., "Fluticasone propionate: an effective alter(cid:173)
`native treatment for seasonal allergic rhinitis in adults and adoles(cid:173)
`cents," The Journal of Family Practice, 1994, vol. 38, No. 2 (Feb), pp.
`145-152, Appleton & Lange.
`Lane, S.
`capillary
`J.,
`et
`al.,
`"Evaluation of a new
`electrochrornatography/rnass spectrometry interface using short col(cid:173)
`umns and high field strengths for rapid and efficient analyses," Rapid
`Communications in Mass Spectrometry, vol. 10, 1996, pp. 733-736,
`John Wiley & Sons, Ltd.
`Li, Zheng, et al., "Synthesis of aryl 5-(2-chlorophenyl)-2-furoates
`under phase transfer catalysis," Synthetic Communications, vol. 32,
`No. 20, pp. 3081-3086, 2002, Marcel Dekker, Inc.
`Linder, A., "Symptom scores as measures of the severity ofrhinitis,"
`Clinical Allergy, 1988, vol. 18, pp. 29-37.
`Lumry, William R., "A review of the preclinical and clinical data of
`newer intranasal steroids in the treatment of allergic rhinitis," J
`Allergy Clin Immunol, Oct. 1999, vol. 104, No. 4, Part 1, pp. Sl50-
`Sl58 plus correction p. 394 dated Feb. 2000, Mosby, Inc.
`Lyseng-Williamson, Katherine A., et al., "Inhaled salmeterol/
`fluticasone propionate combination in chronic obstructive pulmo(cid:173)
`nary disease," Am J Respir Med, vol. 1, No. 4, 2002, pp. 273-282,
`Adis International Limited.
`Malhotra Exhibit A, Aug. 2011, 7 pages.
`Malhotra Exhibit B, Aug. 2011, 6 pages.
`Maus Exhibit B, Aug. 2011, 2 pages.
`May, Percy, et al., "May's Chemistry of Synthetic Drugs," Fifth
`Edition, 1964, pp. 12-17 plus cover and publishing pages, Longmans.
`Mealy, N. E., et al., "Ciclesonide: treatment of allergic rhinitis
`antiallergy/antiasthmatic," XP009041019, Drugs of the Future, vol.
`26, No. 11, Nov. 2001, pp. 1033-1039, Prous Science.
`Meltzer, Eli 0., "Allergic rhinitis: Managing the pediatric spectrum,"
`Allergy and Asthma Proceedings, Jan.-Feb. 2006, vol. 27, No. 1, pp.
`2-8, Oceanside Publications, Inc., U.S.A.
`Meltzer, Eli 0., et al., "Onset of therapeutic effect of fluticasone
`propionate aqueous nasal spray," Annals of Allergy, Asthma, &
`Immunology, Mar. 2001, vol. 86, No. 3, pp. 286-291.
`
`

`

`US 9,259,428 B2
`Page 6
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Millard, Jeffrey W., et al., "Solubilization by co solvents establishing
`useful constants for